Bristlecone Advisors LLC Has $1.26 Million Stock Holdings in Pfizer Inc. $PFE

Bristlecone Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 34.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 49,316 shares of the biopharmaceutical company’s stock after selling 26,177 shares during the quarter. Bristlecone Advisors LLC’s holdings in Pfizer were worth $1,257,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Capital Advisory Group Advisory Services LLC grew its stake in shares of Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 388 shares during the last quarter. Citizens National Bank Trust Department lifted its holdings in shares of Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after purchasing an additional 395 shares in the last quarter. Peak Asset Management LLC boosted its holdings in shares of Pfizer by 1.4% in the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after buying an additional 402 shares during the period. Able Wealth Management LLC increased its holdings in Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock worth $512,000 after purchasing an additional 413 shares in the last quarter. Finally, Boltwood Capital Management raised its holdings in shares of Pfizer by 0.7% in the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock valued at $1,485,000 after purchasing an additional 420 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.7%

PFE stock opened at $25.48 on Monday. The company has a market capitalization of $144.84 billion, a PE ratio of 14.81 and a beta of 0.47. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The company’s 50-day simple moving average is $25.26 and its 200 day simple moving average is $24.96.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio is presently 100.00%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PFE. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. HSBC reissued a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Scotiabank assumed coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. Finally, UBS Group initiated coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $27.88.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 data for a PADCEV + Keytruda bladder‑cancer combo bolsters Pfizer’s oncology franchise and revenue outlook; clinical validation can drive upside for PFE if regulatory and commercial plans follow. Pfizer, Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment
• Positive Sentiment: Real‑world breast cancer study update signals Pfizer is pushing strategically in the HER2‑positive space — a reminder of ongoing pipeline commercialization opportunities beyond legacy products. Pfizer’s Real‑World Breast Cancer Study Signals Strategic Push in HER2-Positive Market
• Positive Sentiment: Coverage of Pfizer’s AI and precision‑oncology deals highlights a shift in the investment story toward higher‑growth, tech‑enabled oncology programs — can improve long‑term growth perception. How Pfizer’s AI and Precision Oncology Deals Have Changed Its Investment Story
• Positive Sentiment: Partnership with Gordian Bio to probe new obesity targets strengthens Pfizer’s exposure to the high‑growth weight‑loss drug market — a strategic priority highlighted in recent sector narratives. Pfizer partners Gordian Bio to probe new obesity targets
• Positive Sentiment: Broader healthcare sector rebound (VHT coverage) is attracting flows to undervalued pharma names like Pfizer, supporting multiple expansion and demand for dividend/defensive stocks. This ETF Is Proof That the Healthcare Rebound Is Real
• Neutral Sentiment: JPMorgan Healthcare Conference preview: JPM will likely produce company updates and M&A headlines that can move PFE intraday — a near‑term volatility catalyst but outcome‑dependent. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Unusual options flow: heavy activity in March PFE puts (March 20 $29 put highest Vol/OI) — could reflect hedging or directional bearish bets; watch open interest and dealer delta for short‑term price pressure. Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On
• Negative Sentiment: Analyst/retail pieces predicting other healthcare stocks will outperform Pfizer and commentary about a recent ~6% drop signal negative sentiment and may pressure PFE if doubts about growth persist. Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 Pfizer’s Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.